{
    "clinical_study": {
        "@rank": "129627", 
        "acronym": "LeeBLet", 
        "arm_group": {
            "arm_group_label": "LEE011 + buparlisib + letrozole", 
            "arm_group_type": "Experimental", 
            "description": "open label, dose escalation evaluating max tolerated dose of the triple combination"
        }, 
        "brief_summary": {
            "textblock": "This is a multi-center, open-label, non-randomized, phase I study"
        }, 
        "brief_title": "Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced or Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Women with advanced (recurrent or metastatic) breast cancer who received no prior\n             therapy for advanced disease.\n\n          2. Patient is postmenopausal.\n\n          3. Patient may have received \u2264 2 lines of chemotherapy for metastatic or recurrent\n             breast cancer in the dose-escalation phase.\n\n          4. Patient has a histologically and/or cytologically confirmed diagnosis of\n             estrogen-receptor positive and/or progesterone receptor positive breast cancer by\n             local laboratory.\n\n          5. Patient has HER2-negative breast cancer defined as a negative in situ hybridization\n             test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization\n             (FISH, CISH, or SISH) test is required by local laboratory testing.\n\n          6. Patient must have either:\n\n               -  Measurable disease, i.e., at least one measurable lesion as per RECIST 1.1\n                  criteria or at least one predominantly lytic bone lesion\n\n        Exclusion Criteria:\n\n          1. Patient who received any CDK4/6 or PI3K inhibitor.\n\n          2. Patient has active cardiac disease or a history of cardiac dysfunction including any\n             of the following:\n\n               -  History of angina pectoris, symptomatic pericarditis, or myocardial infarction\n                  within 12 months prior to study entry\n\n               -  History of documented congestive heart failure (New York Heart Association\n                  functional classification III-IV)\n\n               -  Documented cardiomyopathy\n\n               -  Patient has a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by\n                  Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)\n\n               -  History of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal\n                  arrhythmias, or conduction abnormality in the previous 12 months.\n\n               -  On screening, any of the following cardiac parameters: bradycardia (heart rate <\n                  50 at rest), tachycardia (heart rate > 90 at rest), PR interval > 220 msec, QRS\n                  interval >109 msec, or QTcF >450 msec.\n\n             Systolic blood pressure >160 or <90 mmHg\n\n          3. Patient is currently receiving any of the following medications:\n\n               -  That are known strong inducers or inhibitors of CYP3A4.\n\n               -  That have a known risk to prolong the QT interval or induce Torsades de Pointes.\n\n               -  That have a narrow therapeutic window and are predominantly metabolized through\n                  CYP3A4.\n\n          4. Certain scores on an anxiety and depression mood questionnaires"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02154776", 
            "org_study_id": "CLEE011A2112C"
        }, 
        "intervention": [
            {
                "arm_group_label": "LEE011 + buparlisib + letrozole", 
                "description": "3 weeks on and 1 week off", 
                "intervention_name": "LEE011", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LEE011 + buparlisib + letrozole", 
                "description": "daily", 
                "intervention_name": "Buparlisib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LEE011 + buparlisib + letrozole", 
                "description": "2.5 mg daily;", 
                "intervention_name": "Letrozole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Letrozole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "LEE011,", 
            "buparlisib,", 
            "letrozole,", 
            "HR +,", 
            "HER2 - negative,", 
            "post-menopausal,", 
            "breast cancer,", 
            "CDK 4/6,", 
            "PI3K,", 
            "MTD"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "CMaravola@mednet.ucla.edu", 
                    "last_name": "Christine Maravola", 
                    "phone": "310-582-6324"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "University of California at Los Angeles UCLA SC"
                }, 
                "investigator": {
                    "last_name": "Sara Hurvitz", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jkeenoy@horizonbioadvance.com", 
                    "last_name": "Julia Keenoy", 
                    "phone": "765-250-4477"
                }, 
                "facility": {
                    "address": {
                        "city": "Lafayette", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "47905"
                    }, 
                    "name": "Horizon Oncology Center SC"
                }, 
                "investigator": {
                    "last_name": "Wael Harb", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Christine.bonney@uphs.upenn.edu", 
                    "last_name": "Christine Bonney"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadephia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "University of Pennsylvania Medical Center SC-4"
                }, 
                "investigator": {
                    "last_name": "Angela DeMichele", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "idspharm@musc.edu", 
                    "last_name": "Kimberly Porter", 
                    "phone": "843-792-9007"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina SC"
                }, 
                "investigator": {
                    "last_name": "Sara Giordano", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Theresa.mays@start.stoh.com", 
                    "last_name": "Theresa A. Mays"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "789229"
                    }, 
                    "name": "South Texas Accelerated Research Therapeutics SC"
                }, 
                "investigator": {
                    "last_name": "Amita Patnaik", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "lynda.staples@hci.utah.edu", 
                    "last_name": "Lynda Staples", 
                    "phone": "801-587-4567"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84103"
                    }, 
                    "name": "University of Utah / Huntsman Cancer Institute SC-3"
                }, 
                "investigator": {
                    "last_name": "Theresa Werner", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28009"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole for the Treatment of HR+, HER2-negative Post-menopausal Women With Locally Advanced or Metastatic Breast Cancer.", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Dose Escalation Phase: Frequency of DLTs at each dose level associated with administration of LEE011, buparlisib, and letrozole in a 28 day cycle", 
                "measure": "Incidence of dose-limiting toxicities (DLTs)", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Dose Expansion Phase: Incidence of AEs, SAEs (overal and severity), laboratory abnormalities, ECG, vital, dose interteruptions, dose reductions, and dose intensity as a measure of safety and tolerability.", 
                "measure": "Safety and tolerability of the combination of LEE011, buparlisib, and letrozole", 
                "safety_issue": "Yes", 
                "time_frame": "approximately 25 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02154776"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Dose Escalation Phase: Incidence of AEs, SAEs (overall and severity), laboratory abnormalities, ECG, vital, dose interterruptions, dose reductions, and dose intensity as a measure of safety and tolerability.", 
                "measure": "Safety and tolerabiity of the combination of LEE011, buparlisib, and letrozole", 
                "safety_issue": "Yes", 
                "time_frame": "approximately 25 months"
            }, 
            {
                "description": "Dose Escalation Phase: When given in combination as well any other clinically significant metabolites that may be identified", 
                "measure": "Pharmacokinetic paramters such as AUClast and Cmax of LEE011, buparlisib, and letrozole in order to characterize the PK profiles", 
                "safety_issue": "No", 
                "time_frame": "approximately 25 months"
            }, 
            {
                "description": "Dose Expansion Phase: When given in combination as well as any other clinically significant metabolites that may be identified", 
                "measure": "Pharmacokinetic paramters such as AUClast and Cmax of LEE011, buparlisib, and letrozole in order to characterize the PK profiles", 
                "safety_issue": "No", 
                "time_frame": "approximately 25 months"
            }, 
            {
                "description": "Dose Expansion Phase: Proportion of patients with the best overall response of CR (complete response), PR (partial response), or SD (stable disease)", 
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 25 months"
            }, 
            {
                "description": "Dose Expansion Phase: Time from date of start of treatment to date of first documented progression or death due to any cause.", 
                "measure": "PFS (progression free survival)", 
                "safety_issue": "No", 
                "time_frame": "approximately 25 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}